RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
  Clinical Trials
  Myocardial Infarction
 Clinical Trials
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM

subscribe to CAD newsletter
Latest Research : Cardiology : CAD

   EMAIL   |   PRINT
Adding abciximab to the antithrombotic regimen significantly reduces post-stent complications

Mar 19, 2006 - 3:02:00 AM , Reviewed by: Rashmi Yadav
"Together with other current trials, this will help to define the current optimal adjunct antithrombotic therapy in patients with ACS managed with PCI."

[RxPG] Patients admitted to the hospital with an acute coronary syndrome (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention, or PCI. But doctors are unclear about the optimal antithrombotic therapy to prescribe after procedure to prevent clotting, and new research suggests a possible alternative, according to a study presented today at the American College of Cardiology's 55th Annual Scientific Session. ACC.06 is the premier cardiovascular medical meeting, bringing together more than 30,000 cardiologists to further breakthroughs in cardiovascular medicine.

Previous research has shown that adding the antithrombotic drug abciximab, (a glycoprotein IIb/IIIa receptor inhibitor) to therapy with ticlopidine plus aspirin significantly reduces post-stent implantation complications, including death, repeat heart attack or reintervention. The drug ticlopidine has been replaced by clopidogrel in recent research, which is safe and acts more rapidly in a 600 mg dosage level, offering better platelet inhibition within two hours of administration.

In a previous trial of low-to-moderate risk patients, the use of clopidogrel was associated with such a low frequency of early complications that the use of abciximab offered no clinical benefit. However, higher risk patients with ACS may benefit from a more potent antithrombotic regimen. The ISAR-REACT 2 trial evaluated for the first time the value of abciximab in patients with ACS undergoing PCI after pretreatment with 600 mg of clopidogrel.

"No specifically designed randomized studies have previously been conducted on the value of abciximab plus a high-dose of clopidogrel during PCI in ACS patients," said Adnan Kastrati, M.D., of the Deutscshes Herzzentrum Munich, Germany and lead author of the study. "Together with other current trials, this will help to define the current optimal adjunct antithrombotic therapy in patients with ACS managed with PCI."

The randomized, multi-center, double-blind, placebo controlled study of 2,022 patients undergoing PCI after pretreatment with clopidogrel were randomized to receive abciximab or placebo. The researchers measured for 30-day combined incidence of death, heart attack or urgent revascularization, as well as bleeding complications. The trial results show the role of the combination - intensive clopidogrel pretreatment plus abciximab - during PCI for ACS. They will enable us to know whether patients with ACS or any subset of them can benefit from this combination.

Dr. Kastrati will present the results of the "Prospective, Double Blind, Placebo-Controlled Trial of Glycoprotein IIb/IIIa Inhibition with Abciximab in Patients with Acute Coronary Syndromes Undergoing Stenting After Pretreatment with a High Loading Dose of Clopidogrel" (ISAR-REACT 2) study on Monday, March 13, at 2:40 p.m.

On the web: http://www.acc.org/ 

Advertise in this space for $10 per month. Contact us today.

Related CAD News
Pericytes from human leg veins may help with recovery after a myocardial infarction
No difference in graft patency between radial and saphenous vein grafts in CABG procedures
Nanoparticles - possible alternative to drug eluting stents
Heart stem/progenitor cells improve mouse heart function after a heart attack
Delayed enhancement cardiovascular magnetic resonance to detect non-Q wave heart attacks
Post-arrest survival better in high volume hospitals
New European guidelines on the management of ST segment elevation myocardial infarction
Bivalirudin during primary angioplasty better than heparin and glycoprotein IIb/IIIa inhibitors (GPI).
Intermittent hypoxic treatment for reduced myocardial infarction and lethal arrhythmias
MDCT accurate in detecting stenosis in calcified coronary artery plaque

Subscribe to CAD Newsletter

Enter your email address:

 Additional information about the news article
The American College of Cardiology (www.acc.org) represents the majority of board certified cardiovascular physicians in the United States. Its mission is to advocate for quality cardiovascular care through education, research, promotion, development and application of standards and guidelines- and to influence health care policy. ACC.06 and the ACC inaugural i2 Summit, the first-ever meeting for interventional cardiologists, will bring together more than 30,000 cardiologists and cardiovascular specialists to share the newest discoveries in the treatment and prevention, while helping the ACC achieve its mission to address and improve issues in cardiovascular medicine.
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)